Efficacy and safety of osilodrostat in paraneoplastic Cushing's syndrome: a real-world multicenter study in France.

Alexandre DormoyMagalie HaissaguerreGéraldine VitelliusChristine Do CaoAurore GeslotDelphine DruiHélène LasolleOceana Vieira-PintoSylvie SalenaveMaud FrançoisMarie PuertoHélène Du BoullayAnne MayerAnne RodClaire LaurentPhilippe ChansonYves ReznikFrederic Castinetti Olivier Chabre Eric Baudin Gerald Raverot Antoine Tabarin Jacques Young

Published in: The Journal of clinical endocrinology and metabolism (2022)

Osilodrostat is a rapidly efficient therapy for PNCS/EAS with severe/intense hypercortisolism. Osilodrostat was generally well tolerated; Adrenal insufficiency was the main side effect.

Keyphrases

early onset
case report
drug induced